Managing Ibrutinib-Intolerant Patients With B-Cell Malignancies
The Oncologist · 2023
DOI: 10.1093/oncolo/oyac260 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Oncologist, 2023. Verfasst von Javier Muñoz und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Mayo Clinic, Phoenix, AZ, USA. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell, Lymphoma, B-Cell. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: BeiGene USA.
Abstract (Originalsprache)
Ibrutinib is a first-generation inhibitor of Bruton tyrosine kinase (BTK) that is currently approved to treat patients with B-cell malignancies, including Waldenström macroglobulinemia (WM), relapsed/refractory (R/R) mantle cell lymphoma (MCL), R/R marginal zone lymphoma (MZL), and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Off-target adverse effects, such as atrial fibrillation, hypertension, and bleeding, have been observed and may limit a patient’s tolerance for treatment. Currently, there is no well-established treatment regimen for patients who cannot tolerate ibrutinib. Approaches to address such patients include managing ibrutinib side effects with supportive care or dose reductions, switching to an alternative covalent BTK inhibitor, or abandoning covalent BTK inhibitors for alternative forms of treatment. Here we review the literature and provide guidance on treating ibrutinib-intolerant patients with B-cell malignancies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology and Oncology, Mayo Clinic, Phoenix, AZ, USA.
- Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
ORCID-Profile: Jorge J Castillo
Förderung
- BeiGene USA
Zitieren
APA
Muñoz, J., Sarosiek, S., & Castillo, J. J. (2023). Managing Ibrutinib-Intolerant Patients With B-Cell Malignancies. The Oncologist. https://doi.org/10.1093/oncolo/oyac260
Vancouver
Muñoz J, Sarosiek S, Castillo JJ. Managing Ibrutinib-Intolerant Patients With B-Cell Malignancies. The Oncologist. 2023. doi:10.1093/oncolo/oyac260
BibTeX
@article{Muoz2023,
author = {Muñoz, Javier and Sarosiek, Shayna and Castillo, Jorge J},
title = {Managing Ibrutinib-Intolerant Patients With B-Cell Malignancies},
journal = {The Oncologist},
year = {2023},
doi = {10.1093/oncolo/oyac260}
}
EUVIMED